Schizophrenia Research
Volume 120, Issue 1 , Pages 204-209 , July 2010

Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study

  • Robert C. Smith

      Affiliations

    • Department of Psychiatry, New York University Medical School, United States
    • Manhattan Psychiatric Center, United States
    • Nathan Kline Institute for Psychiatric Research, United States
    • Corresponding Author InformationCorresponding author. NYU Medical School, Dept. Psychiatry, C/o PO Box 316, Hewlett, NY 11557, United States. Tel.: +1 646 672 6910, 516 569 1810; fax: +1 516 569 1755.
    • ,
  • Jean-Pierre Lindenmayer

      Affiliations

    • Department of Psychiatry, New York University Medical School, United States
    • Manhattan Psychiatric Center, United States
    • Nathan Kline Institute for Psychiatric Research, United States
    • ,
  • Qiaoyan Hu

      Affiliations

    • Psychiatric Institute, University of Illinois College of Medicine, United States
    • ,
  • Erin Kelly

      Affiliations

    • Manhattan Psychiatric Center, United States
    • Dept of Psychology, Univ. of California, Irvine.
    • ,
  • Thomas F. Viviano

      Affiliations

    • Manhattan Psychiatric Center, United States
    • Fordham University Graduate School.
    • ,
  • James Cornwell

      Affiliations

    • Manhattan Psychiatric Center, United States
    • ,
  • Sumathi Vaidhyanathaswamy

      Affiliations

    • Manhattan Psychiatric Center, United States
    • New Ulm Medical Center, New Ulm, MN.
    • ,
  • Santica Marcovina

      Affiliations

    • Department of Medicine, University of Washington, Seattle, United States
    • Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, United States
    • ,
  • John M. Davis

      Affiliations

    • Psychiatric Institute, University of Illinois College of Medicine, United States

Received 20 December 2009 ,Accepted 8 April 2010.

References 

  1. Bansal S, Buring J, Rifai N, Mora S, Sacks F, Ridker P. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–316
  2. Barak Y, Aizenberg D. Effects of olanzapine on lipid abnormal ties in elderly psychotic patients. Drugs and Aging. 2003;20:893–896
  3. Cohn J. Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?. Atherosclerosis. 2008;Supplements 9:15–18
  4. Correll C, Manu P, Olshanskiy V, Napolitano B, Kane J, Malhotra A. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–1773
  5. Dietrich-Muszalska A, Rabe-Jablonska J, Nopwak P, Kontek B. The first- and second-generation antipsychotic drugs affect ADP-induce plantlet aggregation. World Journal of Biological Psychiatry. 2009;1–8Epublication. 12-19-2009
  6. Eberly L, Stamler J, Neaton J. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine. 2003;163:1077–1083
  7. Grundy SM, Brewer HB, Cleeman JJ, Smith SC, Lenfiant C. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  8. Hardy T, Marquez E, Kryzhanovskaya L, Taylor C, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. Journal of Clinical Psychopharmacology. 2006;26:405–408
  9. Kelly D, Wehring H, Linthicum J, Feldman S, McMahon R, Love R, et al. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia Research. 2009;107:134–138
  10. Lairon D, Lopez-Miranda J, Williams C. Methodology for studying postprandial lipid metabolism. European Journal of Clinical Nutrition. 2007;61:1145–1161
  11. Lieberman J, Stroup T, MCevoy J, Swartz M, Rosenheck R, Perkins D, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223
  12. Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy J, et al. Changes in glucose and cholesterol levels in patient with schizophrenia treated with typical and atypical antipsychotics. American Journal of Psychiatry. 2003;160:290–296
  13. Lindenmayer J-P, Khan A, Wance D, Maccabee N, Kaushik S, Kaushik S. Outcome evaluation of a structured educational wellness program in patients with severe mental illness. The Journal of Clinical Psychiatry. 2009;70:1385–1396
  14. Meyer J, Davis V, Goff D, McEvoy J, Nasrallah H, Davis S, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research. 2008;101:273–286
  15. Meyer J, Koro C. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research. 2004;70:1–17
  16. Meyer JL, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Scand. 2009;119:4–14
  17. Newcomer J. Second -generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl1):1–94
  18. Newcomer J, Ratner R, Eriksson J, Emsley R, Meulien D, Miller F, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. The Journal of Clinical Psychiatry. 2009;70:487–499
  19. Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308
  20. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Current Drug Targets. 2009;10:328–335
  21. Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacology. 2005;8:183–194
  22. Smith R, Lindenmayer J, Davis J, Kelly E, Viviano T, Cornwell J, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. The Journal of Clinical Psychiatry. 2009;70:1501–15138, 228–236
  23. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatrica Scandinavia. 2009;119:171–179
  24. Tilhonen JJL, Wahlbeck K, Klaukka T, Niakanen L, Tenskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FN11study). Lancet. 2009;374:620–627

PII: S0920-9964(10)01254-5

doi: 10.1016/j.schres.2010.04.001

Schizophrenia Research
Volume 120, Issue 1 , Pages 204-209 , July 2010

Article Tools